CompletedPhase 2

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

United States327 participantsStarted 2021-09-16

Plain-language summary

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease

Who can participate

Age range60 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Gradual and progressive change in memory function reported by participants or informants for ≥ 6 months * MMSE score of 22 to 30 (inclusive) at screening * CDR global score of 0.5 to 1.0 (inclusive), with a memory box score ≥0.5. * Meet 18F flortaucipir positron emission tomography (PET) scan (central analysis) criteria * Have a study partner who will provide written informed consent to participate Exclusion Criteria: * Contraindication to MRI or PET scans * Have known allergies to LY3372689, related compounds, or any components of the formulations

What they're measuring

Change From Baseline to End Time Point in Integrated Alzheimer's Disease Rating Scale (iADRS) (Intermediate (Low-medium) Tau Population)

Timeframe: Baseline, Week 100

Trial details

NCT IDNCT05063539

SponsorEli Lilly and Company

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-07-09

Results submitted2025-07-09

View on ClinicalTrials.gov More Alzheimer Disease trials